PACIRA BIOSCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements
PACIRA BIOSCIENCES, INC. (PCRX) reported Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements of 585.00 thousand shares for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements · last filed 2020-05-07
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2020-03-31 was 585.00K shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2019-06-30 was 3.00K shares, a 25.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2019-03-31 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for the quarter ending 2018-06-30 was 4.00K shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2017 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2015 was 1.00K shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of equity unit purchase agreements for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements 12 month |
|---|---|---|---|---|
| 2020-03-31 | 585.00K shares 10-Q · filed 2020-05-07 | |||
| 2019-06-30 | 3.00K shares 10-Q · filed 2019-08-08 | 0.00 shares 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-07 | |||
| 2018-06-30 | 4.00K shares 10-Q · filed 2019-08-08 | 0.00 shares 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2017-06-30 | 0.00 shares 10-Q · filed 2018-08-02 | 0.00 shares 10-Q · filed 2018-08-02 | ||
| 2016-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-02 | 0.00 shares 10-Q · filed 2016-11-02 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | 0.00 shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | 1.00K shares 10-K · filed 2018-02-28 | |||
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-02 | 1.00K shares 10-Q · filed 2016-11-02 | ||
| 2015-06-30 | 1.00K shares 10-Q · filed 2016-08-04 | 1.00K shares 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 1.00K shares 10-Q · filed 2016-05-02 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-01 | 0.00 shares 10-K · filed 2016-02-25 | ||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-10-27 | 0.00 shares 10-Q · filed 2015-10-27 | ||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-07-30 | 0.00 shares 10-Q · filed 2015-07-30 | ||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-04-30 | |||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |